Print Page     Close Window     
6-K
MESOBLAST LTD filed this Form 6-K on 08/31/2018
Entire Document
 

Slide 4

Premier global cellular medicines company Multiple Revenue Generating Products & Phase 3 Assets Industrial Scale Manufacturing Disruptive Technology Platform1 Immuno-selected, culture expanded cellular medicines Well characterized mechanisms of action targeting multiple pathways Extensive, robust IP estate Targeting the most severe disease states refractory to conventional therapies Unique cell properties enable large scale expansion and use in unrelated recipients Proprietary media formulations meet industrial scale needs ‘Off the shelf’ delineated products with batch to batch consistency and reproducibility 2 approved products commercialized by licensees in Japan2 and Europe3 3 product candidates in U.S. Phase 3 Major near-term data readouts Revenue from approved and late-stage assets will help fund deep product pipeline Mesenchymal precursor cells (MPCs) and their culture-expanded progeny mesenchymal stem cells (MSCs). TEMCELL® Hs Inj licensee JCR Pharmaceuticals Co., Ltd. received the first full PMDA approval for an allogeneic cellular medicine in Japan. Alofisel ® licensee Takeda received first central marketing authorization (MA) approval from the European Commission (EC) for an allogeneic stem cell therapy.


Copyright © 2015 Mesoblast Inc.